PURDUE DRUG PRICING STUDY "IN NO WAY" SUPPORTS
PURDUE DRUG PRICING STUDY "IN NO WAY" SUPPORTS arguments against increasing Medicaid reimbursement levels to pharmacies," the primary author of the study Joseph Thomas, PhD, maintained in an Oct. 4 letter to "The Pink Skeet." The Thomas letter notes that "the report is based on an analysis of prices and charges for all prescriptions dispensed in retail pharmacies for the study drugs. The data is not limited to Medicaid prescriptions." Thomas added that "other Medicaid specific data show declines in pharmacy margins under Medicaid." In his letter, Thomas also said that "The Pink Sheet" headline for an article about the study -- "Pharmacy profits kept pace with inflation..." -- is "incorrect." Thomas noted that "one conclusion" of the report is that retail pharmacy net profits decreased during the period covered in the report. The Thomas letter maintains that the report "does not include any findings of any increase or even stability in pharmacy profits." It also emphasizes that "margins do not represent profits. The margin referred to in the report simply represents the difference between what pharmacists paid for pharmaceuticals and the retail prices paid by consumers. It represents the fraction of the price left to pay operating costs such as rent, utilities, employees' wages, and perhaps increased inventory carrying costs associated with more expensive product acquisition prices." "The Pink Sheet" story noted that pharmacy net profits decreased from 1981 to 1988 and that pharmacy profit margins on prescription drugs fell from 35% to 26% in that period. However, the story focused on the report's finding that pharmacy margin levels held steady between 1981 and 1988 when measured in dollar terms, and that in 1981 constant dollars, pharmacy dollar margins increased 33 cents in real dollar terms.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth